APA (7th ed.) Citation

Albrecht, D., Iwashima, M., Dillon, D., Harris, S., & Levy, J. (2020). A Phase 1, Randomized, Open‐Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects. Headache, 60(4), 701-712. https://doi.org/10.1111/head.13737

Chicago Style (17th ed.) Citation

Albrecht, Detlef, Mic Iwashima, Debbie Dillon, Stuart Harris, and Jeff Levy. "A Phase 1, Randomized, Open‐Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects." Headache 60, no. 4 (2020): 701-712. https://doi.org/10.1111/head.13737.

MLA (9th ed.) Citation

Albrecht, Detlef, et al. "A Phase 1, Randomized, Open‐Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects." Headache, vol. 60, no. 4, 2020, pp. 701-712, https://doi.org/10.1111/head.13737.